Stocks and Investing
Stocks and Investing
Fri, August 6, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mani Foroohar Maintained (BBIO) at Buy with Decreased Target to $66 on, Aug 6th, 2021
Mani Foroohar of SVB Leerink, Maintained "BridgeBio Pharma, Inc." (BBIO) at Buy with Decreased Target from $71 to $66 on, Aug 6th, 2021.
Mani has made no other calls on BBIO in the last 4 months.
There are 2 other peers that have a rating on BBIO. Out of the 2 peers that are also analyzing BBIO, 0 agree with Mani's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Mani
- Eliana Merle of "UBS" Initiated at Strong Buy and Held Target at $80 on, Friday, May 21st, 2021
- Paul Choi of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $80 on, Friday, May 7th, 2021
Contributing Sources